Dakterzada, F.
Targa, A.
Benítez, I. D.
Romero-ElKhayat, L.
de Gonzalo-Calvo, D.
Torres, G.
Moncusí-Moix, A.
Huerto, R.
Sánchez-de-la-Torre, M.
Barbé, F.
Piñol-Ripoll, G.
Funding for this research was provided by:
Department of Health, Generalitat Catalunya (SLT008/18/00050)
Fundació la Marató de TV3 (464/C/2014)
Agency for Management of University and Research Grants (FI_B100153)
Article History
Received: 29 July 2020
Accepted: 26 November 2020
First Online: 5 December 2020
Ethics approval and consent to participate
: The Clinical Investigation Ethical Committee (CEIC P16/109) of Arnau de Vilanova University Hospital of Lleida approved the discovery cohort in this study. The included patients for the confirmation cohort signed an internal regulatory document, stating that residual samples used for diagnostic procedures can be used for research studies, without any additional informed consent. Written informed consent was obtained from all patients.
: Not applicable.
: DdGC has filed a patent on the use of miRNAs as biomarkers.